Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical. encoding enzymes for ouabain synthesis. Another argument against endogenous ouabain was the lack of effect when rostafuroxin. The figure below shows the key steps in the synthesis of ouabain. Rostafuroxin ameliorates endothelial dysfunction and oxidative stress. improved acetylcholine-induced relaxation via enhanced nitric oxide synthesis and. Biological Activity. Rostafuroxin (PST 2238) is a new oral antihypertensive agent able to selectively antagonize EO, adducin pressor, and molecular effects. Sigma-Aldrich offers Sigma-SML1139, Rostafuroxin for your research needs. Find product specific information including CAS, MSDS, protocols and references. Rostafuroxin (PST 2238) ist ein Digitoxigenin-Derivat, das als Antagonist des Ouabain (g-Strophanthin) dieses kompetitiv von der Na + /K +-ATPase verdrängt. Rostafuroxin ameliorates endothelial dysfunction and oxidative stress in resistance arteries from deoxycorticosterone acetate-salt. nitric oxide synthesis and. An innovative approach to the therapy of essential hypertension. Rostafuroxin (PST2238: 17beta-. and some enzymes involved in EO synthesis and metabolism. View and buy high purity Rostafuroxin from Tocris Bioscience, the leading worldwide supplier of high performance life science reagents Rostafuroxin (PST-2238) is an ouabain-inhibitor counteracting specific forms of hypertension.